Latest news & insights
Boyds appoints Neil Chakrabarti as Chief Financial Officer
Boyds is delighted to announce the appointment of Neil Chakrabarti as Chief Financial Officer. The appointment comes as the company reports a record-breaking 25 percent
Supporting the development and regulatory activities for the AstraZeneca-Oxford COVID-19 vaccine
The approval in December for the emergency use of the AstraZeneca-Oxford COVID-19 vaccine by the MHRA provided another key milestone in the response to the
Alan Boyd joins Taysha Gene Therapies’ independent scientific advisory board
Professor Alan Boyd has joined Taysha Gene Therapies’ newly formed independent scientific advisory board. Taysha Gene Therapies, Inc., a patient-centric gene therapy company focused on
Medical monitor support and advice for FLU-v phase IIb study for influenza
Each year, influenza affects up to 5 million people worldwide and leads to an estimated 650,000 deaths. Currently, the most effective available treatment is an
Dr Bryan Murray joins Clinical and Medical Affairs Team
Dr Bryan Murray has joined Boyds as a Pharmaceutical Physician within the growing Clinical and Medical Affairs team. Bryan Murray is an experienced trials physician
Regulatory affairs team bolstered with appointment of Submissions Compliance and Quality Manager
Navila Rehman has joined Boyds as Submissions Compliance and Quality Manager within the regulatory affairs team. Navila brings over 20 years’ experience in the pharmaceutical
Virtual drug development
Nick Meyers, VP of Product Development at Boyds, spoke at a recent MarketsAndMarkets event on pragmatic drug development solutions for virtual and semi-virtual sponsors. In
IBD & Tea: building trust in new treatments
Professor Alan Boyd took part in ‘ IBD & Tea’, a recent online debate focused on building trust in new treatments and understanding clinical trials,
